DE69430059T2 - Freisetzung und Mobilisierung hämatopoietischer Zellen - Google Patents

Freisetzung und Mobilisierung hämatopoietischer Zellen

Info

Publication number
DE69430059T2
DE69430059T2 DE69430059T DE69430059T DE69430059T2 DE 69430059 T2 DE69430059 T2 DE 69430059T2 DE 69430059 T DE69430059 T DE 69430059T DE 69430059 T DE69430059 T DE 69430059T DE 69430059 T2 DE69430059 T2 DE 69430059T2
Authority
DE
Germany
Prior art keywords
pct
1alpha
mobilization
release
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430059T
Other languages
English (en)
Other versions
DE69430059D1 (de
Inventor
Berisford Comer
John Mccourt
Michael Wood
George Hunter
Mark Edwards
John Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939312343A external-priority patent/GB9312343D0/en
Priority claimed from GB939324252A external-priority patent/GB9324252D0/en
Priority claimed from GB9402188A external-priority patent/GB9402188D0/en
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE69430059D1 publication Critical patent/DE69430059D1/de
Publication of DE69430059T2 publication Critical patent/DE69430059T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69430059T 1993-06-15 1994-06-15 Freisetzung und Mobilisierung hämatopoietischer Zellen Expired - Fee Related DE69430059T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939312343A GB9312343D0 (en) 1993-06-15 1993-06-15 Pharmaceutical use
GB939324252A GB9324252D0 (en) 1993-11-25 1993-11-25 Pharmaceutical use
GB9402188A GB9402188D0 (en) 1994-02-04 1994-02-04 Pharmaceutical use
PCT/GB1994/001284 WO1994028916A1 (en) 1993-06-15 1994-06-15 Release and mobilisation of haematopoietic cells

Publications (2)

Publication Number Publication Date
DE69430059D1 DE69430059D1 (de) 2002-04-11
DE69430059T2 true DE69430059T2 (de) 2002-11-14

Family

ID=27266724

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430059T Expired - Fee Related DE69430059T2 (de) 1993-06-15 1994-06-15 Freisetzung und Mobilisierung hämatopoietischer Zellen

Country Status (8)

Country Link
US (1) US5925568A (de)
EP (1) EP0703784B1 (de)
JP (1) JPH08511263A (de)
AT (1) ATE213952T1 (de)
AU (1) AU6974294A (de)
DE (1) DE69430059T2 (de)
ES (1) ES2172536T3 (de)
WO (1) WO1994028916A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
EP0713495B1 (de) * 1993-06-08 2003-11-05 Smithkline Beecham Corporation Methoden zur erhöhung der biologischen aktivität von chemokinen
US5595973A (en) * 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
GB9426012D0 (en) * 1994-12-22 1995-02-22 British Biotech Pharm Mobilisation of haematopoietic cells
US6713052B1 (en) 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
GB9600559D0 (en) * 1996-01-11 1996-03-13 British Biotech Pharm Use of chemokines
EP0848012A1 (de) * 1996-12-13 1998-06-17 Roche Diagnostics GmbH Verwendung von Polypeptiden zur Behandlung von Thrombozytopenien
JP2002512013A (ja) * 1998-04-22 2002-04-23 カイロン コーポレイション ケモカインを使用することによる遺伝的免疫に対する免疫応答の増強
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
DK1016414T3 (da) 1998-12-17 2005-01-17 Applied Research Systems Humant væksthormon til stimulering af hæmatopoise og immunkonstitution efter transplantation med hæmatopoietiske stamceller i mennesker
EP1016413A1 (de) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Menschliches Wachstumshormon (HGH) zur Stimulierung der Mobilisierung pluripotenter Hämatopoietischer Stammzellen
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
WO2002037968A1 (en) * 2000-11-10 2002-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US20040115175A1 (en) * 2000-11-10 2004-06-17 The Board Of Trustees Of The Leland Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
AU2005326226B2 (en) * 2005-01-31 2010-11-11 Eci, Inc. Immunopotentiating agent
WO2009024426A1 (en) * 2007-07-27 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunizing compositions for inducing 'bystander' killing of pathogens
US8846559B2 (en) * 2008-11-03 2014-09-30 Saudi Basic Industries Corporation Stable shape-selective catalyst for aromatic alkylation and methods of using and preparing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809419D0 (en) * 1988-04-21 1988-05-25 Pragnell I Stem cell inhibitors
CA2064558C (en) * 1989-09-25 2001-01-30 Ian B. Pragnell Method for inhibiting growth of stem cells

Also Published As

Publication number Publication date
AU6974294A (en) 1995-01-03
WO1994028916A1 (en) 1994-12-22
US5925568A (en) 1999-07-20
DE69430059D1 (de) 2002-04-11
ATE213952T1 (de) 2002-03-15
EP0703784A1 (de) 1996-04-03
EP0703784B1 (de) 2002-03-06
ES2172536T3 (es) 2002-10-01
JPH08511263A (ja) 1996-11-26

Similar Documents

Publication Publication Date Title
DE69430059D1 (de) Freisetzung und Mobilisierung hämatopoietischer Zellen
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
DK1131410T3 (da) Gensplejsede vævskonstruktioner og fremgangsmåde til fremstilling og anvendelse deraf
ES2195664T3 (es) Uso de fumaratos de dialquilo.
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
DE69916807D1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
DE69433921D1 (de) Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie
TR200002616T2 (tr) Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
FI971756A0 (fi) CD23:een sitoutuvia aineita
ES2161279T3 (es) Nucleosidos y nucleotidos que contienen racimos de boro.
EE9900105A (et) Bensonaftüridiinid bronhiaalravimitena
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ID22801A (id) Bakteri pelapor bioluminesense dan metode-metode untuk memonitor toksisitas dalam sistim-sistim pengolahan secara biologis
ES2162909T3 (es) Composiciones de fosfolipidos silicona modificadas.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
DE29510554U1 (de) Persönliches Mitteilungsübertragungs- und Empfangssystem für Mehrfachbenutzer
DE69625230T2 (de) Thrombininhibitoren
FR2776188B1 (fr) Oleamide de glycylglycine en dermo-cosmetologie
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
KR950701812A (ko) 렌티바이러스-유도된 질환의 치료에 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido dervatives useful in the treatment of lentivirus-induced sisease)
DK0483237T3 (da) Beskyttelse af cytolytisk aktivitet hos NK-celler i PBMC
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
DK289388A (da) Desinfektionsmiddel til at desinficere hud og overflader paa genstande
DE9319155U1 (de) Hochsitz für Jagd- und Beobachtungszwecke

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee